Summary
Abbott Laboratories (ABT) filed an 8-K on January 27, 2021, to report its fourth quarter and full-year 2020 financial results. The filing primarily references a press release (Exhibit 99.1) containing these results, which includes both GAAP and non-GAAP financial measures. Investors should note that Abbott utilizes non-GAAP measures, such as net earnings excluding specified items, to provide a clearer view of ongoing operational performance by adjusting for unusual or unpredictable factors like acquisition-related expenses, restructuring charges, and tax benefits. While the specific financial figures are detailed in the furnished press release, the 8-K highlights the company's methodology for presenting its financial performance. Management believes these non-GAAP figures offer valuable insights into the core business operations and are used internally for performance assessment. Investors are advised to consider these non-GAAP measures alongside GAAP-based financial statements for a comprehensive understanding of Abbott's financial condition.
Key Highlights
- 1Abbott Laboratories announced its Q4 and full-year 2020 financial results on January 27, 2021.
- 2The 8-K filing incorporates a press release (Exhibit 99.1) containing the detailed financial results.
- 3The company utilizes non-GAAP financial measures, such as adjusted net earnings, to present its performance.
- 4Non-GAAP measures exclude items like acquisition expenses, restructuring charges, R&D asset costs, impairment charges, litigation settlements, and certain tax benefits.
- 5Abbott's management believes these non-GAAP measures provide better visibility into ongoing business performance.
- 6These non-GAAP measures are used internally by management to assess business performance.
- 7Investors are encouraged to consider non-GAAP measures in conjunction with GAAP measures.